Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
US Department of Justice
Colorcon
Harvard Business School
Teva
Medtronic
Cantor Fitzgerald
Julphar

Generated: April 26, 2018

DrugPatentWatch Database Preview

ALDARA Drug Profile

« Back to Dashboard

Which patents cover Aldara, and what generic alternatives are available?

Aldara is a drug marketed by Medicis and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

The generic ingredient in ALDARA is imiquimod. There are fourteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the imiquimod profile page.
Drug patent expirations by year for ALDARA
Pharmacology for ALDARA
Synonyms for ALDARA
(non-labelled)Imiquimod-d9
011I026
1-(2-methylpropyl)-1H-imidazo[4,5-c]-quinolin-4-amine
1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine
1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine;
1-(2-Methylpropyl)-1H-imidazole[4,5-c]quinoline-4-amine
1-(2-methylpropyl)-1Himidazo[4,5-c]quinolin-4-amine
1-(2-methylpropyl)-4-imidazo[4,5-c]quinolinamine
1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine
1-isobutyl-1H-imidazo [4,5-c]quinolin-4-amine
1-isobutyl-1H-imidazo(4,5-c)quinolin-4-amine
1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-ylamine
1-isobutyl-1H-imidazo[4,5-c]quinoline-4-amine
1-isobutylimidazo[4,5-c]quinolin-4-amine
1H-Imidazo(4,5-c)quinolin-4-amine, 1-(2-methylpropyl)-
1H-Imidazo[4, 1-(2-methylpropyl)-
1H-Imidazo[4,5-c]quinolin-4-amine, 1-(2-methylpropyl)-
3M Brand of Imiquimod
4-Amino- 1-isobutyl-1H-imidazo[4,5-c]quinoline; 1-(2-Methylpropyl)-1H-imidazo[4,5-C]quinolin-4-amine
4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline
4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinoline
6T0
9050-31-1
99011-02-6
A845945
AB00399298_08
AB00399298_09
AB00399298-05
AB00399298-06
AB00399298-07
AC-529
AC1L1N2I
AC1Q4YO9
ACMC-209stx
AK209015
AKOS005507352
Aldara (TN)
Aldara, Imiquimod
Aldara|||Beselna
AN-15735
ANW-41635
AOB6939
API0002986
BB_SC-2107
BBL010772
BC205676
BDBM50240849
Beselna
Beselna (TN)
BG0561
BIDD:GT0859
BRD-K26657438-001-13-7
C-14410
CAS-99011-02-6
CC-23827
CCG-208015
CHEBI:36704
CHEMBL1282
CJ-16235
CS-2058
CTK8B3025
D02500
D06CTE
DB00724
DOUYETYNHWVLEO-UHFFFAOYSA-N
DR000569
DSSTox_CID_21047
DSSTox_GSID_41047
DSSTox_RID_79617
DTXSID7041047
DZ-2636
EBD27815
FT-0080222
FT-0602727
GP9049
GTPL5003
HMS2090M14
HMS2232G07
HMS3373B13
HY-B0180
I06-0624
I0747
IMIQUIMOD
Imiquimod / 1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-C]Q
Imiquimod - Aldara
Imiquimod (JAN/USAN/INN)
Imiquimod [USAN:INN]
Imiquimod acetate
Imiquimod, >=98% (HPLC), solid
Imiquimod, United States Pharmacopeia (USP) Reference Standard
Imiquimodum
J10325
KB-52632
KS-000002KB
KS-5218
LS-178395
MCULE-9421195760
MFCD00866946
MLS000083577
MolPort-002-507-845
MTD-39
NCGC00070736-02
NCGC00070736-03
NCGC00070736-04
NSC-369100
NSC-759651
NSC369100
NSC759651
P1QW714R7M
Pharmakon1600-01502351
PL019867
PL076468
PubChem21071
R 837
R-837
S 26308
S-26308
s1211
SC-17224
SCHEMBL26136
SMR000048307
SR-01000611320
SR-01000611320-2
STK583860
SY017571
TL8006059
TMX 101
TMX-101
Tox21_110985
Tox21_110985_1
TR-038644
TRA0092888
UNII-P1QW714R7M
Vyloma
Z-4416
Zartra
ZINC19632912
ZLA0010
zlchem 9
Zyclara
Zyclara (TN)

US Patents and Regulatory Information for ALDARA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Medicis ALDARA imiquimod CREAM;TOPICAL 020723-001 Feb 27, 1997 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ALDARA
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Cream 5% ➤ Subscribe 2006-10-17

Non-Orange Book US Patents for ALDARA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,835,394 Treatment for basal cell carcinoma ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Harvard Business School
Fuji
McKinsey
Express Scripts
Colorcon
Merck
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.